Gui Jia
Overview
Explore the profile of Gui Jia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ding D, Jia G, Cui L, Liu Y, Wang X, Sun R, et al.
Dig Liver Dis
. 2025 Jan;
PMID: 39809678
Background: Positivity for anti-gp210 and anti-centromeric antibodies (ACA) in patients with primary biliary cholangitis (PBC) have been associated with the progression of liver failure and portal hypertension (PH), respectively. The...
2.
Ding D, Hu Y, Jia G, Wang B, Zheng L, Deng J, et al.
Hepatol Int
. 2024 Dec;
PMID: 39661270
Background: Some patients treated with ursodeoxycholic acid (UDCA) or combined fenofibrate had well-controlled biochemical parameters but high liver stiffness, and the prognosis as well as therapeutic options for these patients...
3.
Liu Y, Jia G, Ding D, Zheng L, Sun R, Wang X, et al.
J Dig Dis
. 2024 Feb;
25(1):61-69.
PMID: 38408848
Objectives: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that affects the quality of life (QoL) of patients. This study aimed to evaluate the differences in perceptions of...
4.
Zheng L, Tian S, Yang C, Li B, Jia G, Liu Y, et al.
Clin Gastroenterol Hepatol
. 2024 Feb;
22(6):1265-1274.e19.
PMID: 38354969
Background & Aims: Hypercholesterolemia is frequently diagnosed in patients with primary biliary cholangitis (PBC). However, its association with the prognosis and lipid metabolism is unknown. In this study, we aimed...
5.
Tian S, Guo G, Zhou X, Liu Y, Jia G, Zheng L, et al.
Stem Cell Res Ther
. 2024 Jan;
15(1):8.
PMID: 38167085
Background: Stem cell transplantation shows great potential to improve the long-term survival of cirrhosis patients. However, therapeutic effects may not be homogeneous across the whole study population. This study constructed...
6.
Ding D, Guo G, Cui L, Jia G, Wang X, Zhang M, et al.
Hepatol Int
. 2023 Sep;
18(1):206-215.
PMID: 37725332
Background: The role of liver stiffness measurements (LSM) in patients with primary biliary cholangitis (PBC) remains to be further elucidated. Aims: To clarify the prognostic role of LSM and to...
7.
Liu Y, Guo G, Zheng L, Sun R, Wang X, Deng J, et al.
Am J Gastroenterol
. 2023 Mar;
118(11):1973-1979.
PMID: 36892506
Introduction: Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease, and patients with inadequate response to ursodeoxycholic acid (UDCA) treatment show reduced long-term survival. Recent studies have shown that...
8.
Ding D, Ren P, Guo G, Liu Y, Yang C, Zheng L, et al.
Gastroenterol Hepatol
. 2023 Jan;
46(9):692-701.
PMID: 36632973
Background: Although patients with advanced liver disease have been included in studies evaluating fibrates for the treatment of primary biliary cholangitis (PBC), the frequency of biochemical responses and adverse effects...
9.
Yang C, Guo G, Li B, Zheng L, Sun R, Wang X, et al.
Hepatol Int
. 2022 Oct;
17(1):237-248.
PMID: 36309918
Background And Aims: Current treatment guidelines recommend ursodeoxycholic acid (UDCA) as the first-line treatment for new-diagnosed primary biliary cholangitis (PBC) patients. However, up to 40% patients are insensitive to UDCA...
10.
Ding D, Guo G, Liu Y, Zheng L, Jia G, Deng J, et al.
Hepatol Commun
. 2022 Oct;
6(12):3487-3495.
PMID: 36213941
Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA). However, the efficacy and safety of FF in...